Manager TitleAgeSince
Chief Operating Officer - 2022-11-13
Director TitleAgeSince
Director/Board Member 61 2005-08-15
Chairman 67 2014-09-18
Director/Board Member 55 2008-06-04
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.44%+14.82%+56.31%+91.58% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
+0.93%+3.98%+39.76%-15.11% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average -2.45%+3.63%+56.90%+197.61% 31.17B
Weighted average by Cap. +0.02%+5.69%+57.08%+164.22%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14